Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,769.24
(
-0.11%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.41
(
-2.04%
)
Bitcoin
70,486.46
(
-1.06%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 140287

Friday, 06/28/2013 2:34:15 PM

Friday, June 28, 2013 2:34:15 PM

Post# of 257262

Biosimilar infliximab (Remicade)…Celltrion is partnered with HSP for this product.

Apparently, these companies are no longer partnered on Remicade insofar as they received distinct biosimilar approvals from the CHMP today (#msg-89473615). Unless Celltrion and HSP have some kind of profit-sharing agreement pertaining to both drugs, they would seem to be competitors rather than partners in this instance.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now